NCT07716956 Effect of Targeting Upper Normal Serum Magnesium Levels on Norepinephrine Requirements in Septic Shock Patients
| NCT ID | NCT07716956 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Alexandria University |
| Condition | Septic Shock |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-07-30 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2026-07-30 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to assess the effect of targeting upper normal serum magnesium levels on norepinephrine requirements in adult patients with septic shock. The main questions it aims to answer are: 1. Does maintaining upper normal serum magnesium levels lower the total cumulative dose and duration of norepinephrine therapy? 2. Does this approach reduce the intensive care unit (ICU) length of stay, duration of mechanical ventilation and mortality? This study will compare an intervention group to a control group to see the effect of targeting upper normal serum magnesium levels. Participants will: * Have their serum magnesium levels assessed at baseline (Day 0), at three-day intervals (Days 3, 6, 9) thereafter and on the day of norepinephrine discontinuation. * Receive individualized intravenous magnesium sulfate infusions to achieve and maintain the target serum magnesium levels. * Have their demographic data collected and be monitored closely for clinical data, vital signs, Mean Arterial Pressure (MAP), urine output and laboratory parameters.
Eligibility Criteria
Inclusion Criteria: * Male and female adult patients (aged ≥18 years) diagnosed with septic shock. * Resistant septic shock that requires corticosteroids. Exclusion Criteria: * Pregnancy. * Baseline hypermagnesemia (serum magnesium level \> 2.3 mg/dL). * Renal impairment with creatinine clearance (CrCl) \< 10 ml/min. * Mixed shock.
Contact & Investigator
Noha A Hamdy, PhD
STUDY CHAIR
Faculty of Pharmacy, Alexandria University.
Frequently Asked Questions
Who can join the NCT07716956 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Septic Shock. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07716956 currently recruiting?
Yes, NCT07716956 is actively recruiting participants. Contact the research team at asmaa.khamis252@gmail.com for enrollment information.
Where is the NCT07716956 trial being conducted?
This trial is being conducted at Alexandria, Egypt.
Who is sponsoring the NCT07716956 clinical trial?
NCT07716956 is sponsored by Alexandria University. The principal investigator is Noha A Hamdy, PhD at Faculty of Pharmacy, Alexandria University.. The trial plans to enroll 60 participants.